Latest 8-K filings

Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of SYMON-II study enrollment and a strengthened balance sheet with approximately $9.6 million in cash, supporting advancement of its Symphony IL-6 test toward regulatory submission and commercialization.

IREN Limited announced the successful delivery and acceptance of its Horizon 1 AI Cloud deployment by Microsoft, alongside achieving NVIDIA Exemplar Cloud status.

Pyxis Oncology reported Q2 2026 results, announcing a private placement financing of up to $114 million, with approximately $50 million upfront, extending its cash runway into Q2 2027 and providing updates on its MICVO clinical program.

MiNK Therapeutics announced second quarter 2026 financial results and provided positive initial observations from its Phase 2 trial of agenT-797 in acute lung injury, alongside establishing a paid international named-patient access program.

Creative Realities announced record second quarter revenue of $21.5 million and an improved outlook, driven by strong service revenue growth and new major client wins.

Madison Square Garden Sports Corp. announced robust fiscal 2026 fourth quarter and full-year financial results, highlighted by the New York Knicks' NBA Championship win and progress on the proposed spin-off of its New York Rangers business.

Sprinklr, Inc. announced the appointment of Jordi Ribas, Ph.D., a prominent AI and product leader from Microsoft, to its Board of Directors, effective August 17, 2026.

Karyopharm Therapeutics reported Q2 2026 results, with total revenue at $33.4 million, and reaffirmed full-year guidance, while advancing its myelofibrosis program towards an sNDA submission.

Intuitive Machines announced record Q2 2026 revenue of $206 million, up over four times year-over-year, and a record backlog of $1.8 billion, driven by significant new contract awards across commercial, civil, and national security sectors.

Advanced Flower Capital Inc. announced its second quarter 2026 financial results, reporting a net investment income of $3.5 million and an increase in net asset value per share to $8.25.

Cabaletta Bio announced second quarter 2026 financial results, detailing progress in its rese-cel clinical development program for autoimmune diseases and providing updates on manufacturing partnerships.

CorMedix Therapeutics announced robust second quarter 2026 financial results, including $101.9 million in consolidated revenue and $26.0 million in net income, while raising its full-year adjusted EBITDA guidance.

Beacon Financial Corporation presented its Q2 2026 investor update, showcasing improved profitability metrics, strong capital positions, and a strategic focus on commercial lending, while also addressing specific asset quality concerns.

Yesway, Inc. announced strong second quarter 2026 financial results, highlighted by record store contribution, increased net income, and a raised full-year Adjusted EBITDA outlook.

Collegium Pharmaceutical, Inc. has entered into an accelerated share repurchase agreement to buy back $50 million of its common stock as part of an ongoing repurchase program.

Indaptus Therapeutics reported Q2 2026 results, highlighting a significant reduction in operating expenses and net loss, alongside a $12 million private placement, while discontinuing its Decoy20 clinical study and exploring strategic alternatives.

Falcons Beyond Global, Inc. announced its second quarter 2026 financial results, reporting consolidated revenue of $5.6 million, more than double the prior period, alongside a significant Adjusted EBITDA loss.

Abeona Therapeutics announced second quarter 2026 financial results, highlighting a 31% sequential increase in ZEVASKYN net revenue to $11.4 million and securing CMS New Technology Add-On Payment status.

Wabash National Corporation has amended its credit agreement, extending its revolving credit facility to $300 million with an option to increase by $175 million, maturing in August 2031.

Rockwell Medical, Inc. has released an updated corporate presentation on August 13, 2026, providing a general overview of its business and strategic positioning.

ADI Global Distribution Inc. announced record net revenue of $1,286 million for its second quarter of 2026, following its spin-off from Resideo and commencement of trading on the NYSE.

Cellectar Biosciences reported Q2 2026 results, highlighting progress in its iopofosine I 131 and CLR 125 trials, initiation of Phase 3 site activation, and a significant capital raise.

enCore Energy Corp. announced its Q2 2026 financial results, reporting a net loss per share of $0.19 and decreased uranium extraction, while increasing delivery volumes.

Legence Corp. announced record second quarter 2026 financial results, with revenues soaring 111% year-over-year to $1.26 billion and Adjusted EBITDA increasing 114% to $154.6 million, leading to raised full-year 2026 guidance.

Parabilis Medicines announced strong Q2 2026 results, highlighting advancements in zolucatetide trials, a major collaboration with Regeneron, and a robust cash position extending runway to 2030.

Pelthos Therapeutics announced strong second quarter 2026 financial results, with Zelsuvmi net product revenue increasing 45% quarter-over-quarter, alongside updates on pipeline development and financing.

McGraw Hill announced robust fiscal first quarter 2027 financial results, showcasing significant year-over-year growth in revenue, re-occurring revenue, and digital revenue, alongside expanded margins and net income.

Alliance Laundry Holdings Inc. announced robust second quarter 2026 results, featuring a 7% increase in net revenue to $477 million and a 121% surge in net income to $69 million, leading to an upward revision of full-year Adjusted EBITDA guidance.

Rocket Lab Corporation has entered into a new equity distribution agreement to potentially raise up to $1.94 billion, replacing its prior agreement and continuing its at-the-market program, while also announcing significant progress on its Iridium acquisition.

LENSAR, Inc. announced robust second quarter 2026 financial results, showcasing 18% total revenue growth and a significant swing to positive net income and Adjusted EBITDA.